Randomized Phase III Study Comparing Gefitinib With Erlotinib in Patients With Previously Treated Advanced Lung Adenocarcinoma: WJOG 5108L.

doi:10.1200/JCO.2015.63.4154

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Back to search

Article

Randomized Phase III Study Comparing Gefitinib With Erlotinib in Patients With Previously Treated Advanced Lung Adenocarcinoma: WJOG 5108L.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology - 20 Sept 2016

Urata Yoshiko, Katakami Nobuyuki, Morita Satoshi, Kaji Reiko, Yoshioka Hiroshige, Seto Takashi, Satouchi Miyako, Iwamoto Yasuo, Kanehara Masashi, Fujimoto Daichi, Ikeda Norihiko, Murakami Haruyasu, Daga Haruko, Oguri Tetsuya, Goto Isao, Imamura Fumio, Sugawara Shunichi, Saka Hideo, Nogami Naoyuki, Negoro Shunichi, Nakagawa Kazuhiko, Nakanishi Yoichi

Abstract excerpt

PURPOSE: The epidermal growth factor receptor (EGFR) tyrosine kinase has been an important target for non-small-cell lung cancer. Several EGFR tyrosine kinase inhibitors (TKIs) are currently approved, and both gefitinib and erlotinib are the most well-known first-generation EGFR-TKIs. This random...

Topics

Adenocarcinoma
Adenocarcinoma of Lung
Aged
Antineoplastic Agents
Disease-Free Survival
ErbB Receptors
Erlotinib Hydrochloride
Female
Gefitinib

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Humans

Lung Neoplasms

Male

Middle Aged

Mutation

Protein Kinase Inhibitors

Quinazolines

Source

Open in PubMed

Identifiers

PMID: 27022112
DOI: 10.1200/JCO.2015.63.4154

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 30 Aug 2026. Prepared record publication-27022112-2026-08-30.1. Manifest publication-graph-cohort-2026-08-30.1.

Source receipt: PubMed via Helena Literature Corpus, retrieved 30 Aug 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

discussions

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.